the Department of Pharmaceuticals introduced it to regulate pharmaceutical products' production and marketing in India.
The central theme of policy: the new policy aims to reorient the Drug Price Control Order( DPCO) soer that its focus shifts from mere controlling price to the monitoring of price. This policy will see elimination in third party manufacturing of the medicines and loan licensing. The policy asserts that while the drugs to be exported go through a process of stringent quality assurance as per the importing countries' internal requirements, the same is not done for the indigenously manufactured drugs produced for Indian markets.
While the Draft Pharmaceutical Policy 2017 appeared a promising policy, the pharmaceutical industry had not been pleased about the development. Due to many lacunae identified, it is regarded as a half-hearted policy formulation with little thought to deal with substantive issues. There is a need for more comprehensive reform is necessary, which is not clearly envisaged in this draft policy.